To present an updated cost-effectiveness analysis of evolocumab added to standard background therapy compared with standard background therapy alone in patients with very high-risk atherosclerotic cardiovascular disease, reflecting the 2018 ACC/AHA guideline definition and using the new evolocumab list price.
Methods
We used the previously published Fonarow et al 2 Markov model, which considered a US societal perspective and assumed a lifetime horizon to capture the progression of ASCVD. The model was used to assess subsequent major cardiovascular (CV) events as a function of age, sex, low-density lipoprotein cholesterol level, and CV event history. Model outcomes included major CV events (myocardial infarction, ischemic stroke, and CV death), costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Institutional review board approval was not required because this was a model-based analysis, and no human participants were involved. The previously published inputs for ASCVD costs, utilities, and evolocumab intervention effects from the original model were used in this updated analysis.
2 Accordingly, total costs and total QALYs determined by the model for standard background therapy remain unchanged from the original article 2 when baseline CV event rates are aligned. This updated analysis, however, incorporated new data for 2 key model parameters: (1) an evolocumab annual list price of $5850, reflecting the 60% reduction, and (2) a baseline CV event rate in a clinical practice population in the United States, reflecting the definition of patients with VHR ASCVD in the 2018 ACC/AHA guideline. 4 Because the 2018 ACC/AHA guideline has been recently published, 4 there is an understandable lack of real-world evidence for patients with VHR ASCVD. We therefore modeled a range of plausible baseline CV event rates to represent patients with varying risk profiles within the VHR population.
In the FOURIER clinical trial, 1 the baseline CV event rate for patients at VHR was approximately 2-fold that for patients who were not at VHR. The lower bound of the baseline CV event rate range in this analysis was anchored by a rate of 6.4 events per 100 patient-years, using the original population in Fonarow et al, 2 referred to as patients in US clinical practice.
These event rates integrated total CV events, including recurrent events. The upper bound was calculated at 12.3 events per 100 patient-years by multiplying the rate of patients in US clinical practice by the rate ratio of patients at VHR to those not at VHR observed in the FOURIER clinical trial. Finally, a scenario analysis considering a baseline CV event rate of 4.4 events per 100 patient-years, representing FOURIER clinical trial patients at VHR, was considered. Excel 2016 (Microsoft) was used for all statistical analyses.
Results
Evolocumab was associated with both increased costs and improved outcomes when added to standard background therapy compared with standard background therapy alone, including maximally tolerated statin therapy with or without ezetimibe (Table) . Incremental costs varied across the spectrum of CV risk modeled within the population with VHR ASCVD, ranging from $22 228 for a baseline CV event rate of 6.4 events per 100 patient-years to $3411 for a baseline CV event rate of 12.3 events per 100 patient-years. Incremental QALYs gained ranged from 0.39 to 0.44, respectively. The ICERs therefore ranged from $56 655 to $7667 per QALY gained, respectively. Of note, the ICER of $56 665 reflects the original patients in US clinical practice per Fonarow et al 2 after only the reduction in the price of evolocumab to $5850 is considered, before modeling any increase in baseline CV event rate to characterize the spectrum of increased risk across the patients at VHR. For the range of baseline CV event rates in patients with VHR ASCVD in clinical practice, all ICERs were within what the 2018 ACC/AHA guideline considers a high or intermediate value (<$50 000 to <$150 000 per QALY gained). 4 Moreover, most
ICERs were below $50 000 per QALY gained (the high value), corresponding to baseline CV event rate of 6.9 or more events per 100 patient-years ( Figure) . If standard background therapy included maximally tolerated statin therapy with ezetimibe, ICERs would range from $59 331 to $10 584, depending on the varying level of risk within the population at VHR. In the conservative scenario analysis in which a baseline CV event rate of 4.4 events per 100 patientyears was considered, based on the FOURIER clinical trial observed rates for patients at VHR, the ICER was $91 610 (Table) . 
Discussion
We present an updated cost-effectiveness analysis of evolocumab added to standard background therapy, compared with standard background therapy alone, in patients with VHR ASCVD per the 2018 ACC/AHA guideline, using the new evolocumab list price. As noted in the 2018 ACC/AHA guideline, at any given price, the value of PCSK9 inhibitors will be improved by selecting patients at higher risk for the occurrence of CV events. 4 At its new annual list price of $5850, the addition of evolocumab to standard background therapy in patients with VHR ASCVD yields ICERs that meet currently accepted cost-effectiveness thresholds and are consistent with providing high-value care. This updated cost-effectiveness analysis may be useful for payers, clinicians, and those informing the appropriate use of lipid-lowering therapies in the United States, particularly in light of the current access and reimbursement barriers. The 2018 ACC/AHA guideline questioned the value of PCSK9 inhibitors, likely because mid-2018 prices were considered. Likewise, previously published cost-effectiveness analyses of evolocumab based on the FOURIER clinical trial estimated ICERs that were above the generally accepted willingness-to-pay thresholds; however, these analyses were not specifically conducted in patients with VHR ASCVD and did not reflect the current evolocumab list price. 5, 6 For instance, the base case ICER in Fonarow et al 2 is reduced by 79% to an ICER of $56 665 as a result of the decrease in annual list price of 60%. The reduction in list price improved the cost-effectiveness for patients with ASCVD before characterizing patients at VHR, for whom baseline CV event rates would be higher. Despite the improvement in value at the new current list price, a comprehensive disease management approach including a heart-healthy lifestyle across the life course and adherence to standard background therapy, as per current guidelines, should be applied.
A strength of this analysis is that it offers ICERs across a range of baseline CV event rates as a proxy for patients with varying risk profiles within the VHR population. Despite the understandably limited real-world evidence in this very recently defined population, the range of baseline CV event rates considered in this study is plausible and supported by the available literature. For instance, a recent study in Medicare patients at VHR with a history of recent myocardial infarction or ischemic stroke reported a composite 1-year rate of acute coronary syndrome, ischemic stroke, or death of 38.2 events per 100 patient-years. 7 In that study, the 1-year rate of nonfatal myocardial infarction or ischemic stroke was approximately 9 events per 100 patient-years, even before capturing CV death. On the other hand, a recent evaluation of a PCSK9 inhibitor in a subgroup of patients at VHR in the United States applied a baseline CV event rate of 7.2 events per 100 patient-years. 8 These results highlight the importance of future analyses that more precisely quantify the baseline CV event rates estimated from patients with VHR ASCVD in the real world to further understand the cost-effectiveness of evolocumab.
Limitations
There are potential limitations to this study, and the findings should be interpreted within the context of the data inputs, event rates, and modeling assumptions used. The event rate range for patients with VHR ASCVD was estimated using available data from the FOURIER clinical trial and patients in US clinical practice. The results are based on the assumption that clinical benefits of treatment extend beyond the period with direct follow-up. If the levels of persistence with and adherence to evolocumab therapy differ from those modeled, costs, and clinical effectiveness may differ.
Conclusions
At its current list price, the addition of evolocumab to standard background therapy meets accepted cost-effectiveness thresholds across a range of baseline CV event rates in patients with VHR ASCVD in the United States, with very high risk defined by the 2018 ACC/AHA guideline. This updated costeffectiveness analysis may be informative for payers, health systems, and clinicians regarding the appropriate use and value of lipid-lowering therapies in the United States.
